MedTrace Logo

Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy

NCT07354100 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2026-06-16

No results posted yet for this study

Summary

The purpose of this study is to see if lactulose can improve the effectiveness of immunotherapy in patients with advanced cancer.

Conditions

Interventions

DRUG

Lactulose

Lactulose 10 g daily with standard-of-care Immune checkpoint inhibitors (ICIs).

Sponsors & Collaborators

Principal Investigators

  • Daniel Olson · University of Chicago

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-12-15
Primary Completion
2029-04-13
Completion
2029-04-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07354100 on ClinicalTrials.gov